AZNAstraZenecaSigning up patients
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 700 (planned)
- Started
- Aug 6, 2025
- Main results expected
- Mar 31, 2033
- Fully finished
- Apr 30, 2036
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Metastasis-free survival (MFS)
Measured over: Up to approximately 93 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06952803 · record last updated 2026-10-14 · checked 2026-11-09 15:47 UTC